Revolution Medicines developed the KRAS inhibitor daraxonrasib to treat late-stage pancreatic cancer patients

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.